JAC Advance Access published online on August 18, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh381
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Laboratoire d'Antibiologie (UPRES EA-1156), UER de Médecine, 1 rue Gaston Veil, 44035 Nantes Cedex 01, France
* To whom correspondence should be addressed. E-mail: gpotel{at}sante.univ-nantes.fr.
Objectives: The purpose of this experimental study was first to compare the in vivo intrinsic activity of imipenem and cefepime administered as a continuous infusion and to determine their lowest effective serum steady-state concentration (LESSC). Secondly, we studied the effect of combining therapy with tobramycin. Methods: In a Pseudomonas aeruginosa (ATCC 27853) rabbit endocarditis model, Results: The LESSC was between 3x and 4x MIC of cefepime for P. aeruginosa and about 0.25xMIC of imipenem. Combination of tobramycin with each of the two Conclusion: The optimal Css/MIC ratio might differ from one molecule to another. The LESSC of imipenem is lower than that of cefepime, giving a better intrinsic activity in vivo, despite a higher MIC in vitro.
Revised June 18, 2004
Accepted June 29, 2004
Original article
Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics
![]()
Abstract
-lactam antibiotics were administered by continuous infusion over a 24 h treatment period at different doses until the LESSC was reached, i.e. able to achieve a 2-log drop of cfu/g of vegetations versus untreated animals. The effect of adding tobramycin (3 mg/kg once daily) was then studied.
-lactams did not result in any further significant killing.![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
B. Moriyama, S. A Henning, M. M Neuhauser, R. L Danner, and T. J Walsh Continuous-Infusion {beta}-Lactam Antibiotics During Continuous Venovenous Hemofiltration for the Treatment of Resistant Gram-Negative Bacteria Ann. Pharmacother., July 1, 2009; 43(7): 1324 - 1337. [Abstract] [Full Text] [PDF] |
||||
